Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04743661
Title 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pediatric Brain Tumor Consortium
Indications

medulloblastoma

high grade ependymoma

Therapies

Bevacizumab + Irinotecan + Omburtamab I-131 + Temozolomide

Omburtamab I-131

Age Groups: adult | child
Covered Countries USA


No variant requirements are available.